XNAS
NGNE
Market cap408mUSD
Oct 08, Last price
26.50USD
1D
2.44%
1Q
-33.13%
Jan 2017
-91.97%
IPO
-89.36%
Name
Neoleukin Therapeutics Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
-16.40%
Rev. gr., 5y
%
Revenues
0
-100.00%
Net income
-90m
L+20.24%
CFO
-77m
L+9.31%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Neoleukin Therapeutics, Inc. (NLTX) is a biopharmaceutical enterprise focused on developing immune-based treatments for conditions such as cancer, inflammatory responses, and autoimmune diseases, utilizing its proprietary protein design technology. The company's leading investigational therapy is NL-201, a novel protein meticulously crafted to emulate the therapeutic effects of the IL-2/IL-15 cytokines. This product candidate is intended for the management of various malignancies, including renal cell carcinoma and melanoma. The organization, founded in 2003, was previously known as Aquinox Pharmaceuticals, Inc. before officially changing its name to Neoleukin Therapeutics, Inc. in August 2019. Its operations are based out of Seattle, Washington.
Key people
David J. Main
Co-Founder, President and Chief Executive Officer and Chairman of the Board · since 2014
Leslie Aberman
Vice President, Legal Affairs and Intellectual Property · since 2019
David Chilton Mitchell
Vice President - Global Regulatory Affairs & Quality Assurance · since 2014
Barbara Troupin
Chief Medical Officer, Vice President - Clinical Development · since 2016
Samantha Willing
Vice President - People · since 2019
Daniel J. Levitt
Director · since 2008
Director · since 2017
Kelvin M. Neu
Director · since 2017
Director · since 2015
M. Cantey Boyd
Independent Director · since 2019
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||